AnaptysBio (ANAB) Receives a Buy from Wells Fargo
I'm PortAI, I can summarize articles.
Wells Fargo analyst Derek Archila maintained a Buy rating on AnaptysBio with a price target of $81. Barclays also issued a Buy rating, while TR reiterated a Hold rating. Archila, focusing on healthcare stocks, has an average return of 19.1% and a 54.56% success rate. The news highlights analyst opinions and ratings for AnaptysBio.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments